TARS
Tarsus Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +22.2% ·
share flow +30.0% ·
net new positions +18.2%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 100 | +2 | 26.50M | $1.67B | +7 | −5 |
| Q1 2026 | 101 | +5 | 27.05M | $1.90B | +10 | −6 |
| Q4 2025 | 97 | 0 | 27.39M | $2.24B | +2 | −1 |
| Q3 2025 | 16 | 0 | 11.66M | $693.15M | +1 | −2 |
| Q2 2025 | 14 | 0 | 10.63M | $430.62M | — | — |
| Q1 2025 | 11 | +2 | 4.92M | $252.88M | +2 | — |
| Q4 2024 | 9 | 0 | 3.55M | $196.55M | — | — |
| Q3 2024 | 8 | 0 | 2.33M | $76.49M | — | — |
| Q2 2024 | 8 | — | 2.46M | $66.86M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Citadel Advisors ✦ | 992.64K | +1151.1% | $50.99M | 0.1% | ▲ Add | 4 | SEC ↗ ×2 |
| 2 | State Street Global Advisors ✦ (passive) | 910.72K | -0.7% | $46.78M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 865.43K | +3.2% | $44.47M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 4 | Adage Capital Partners ✦ | 510.00K | New | $26.20M | 0.0% | New | 1 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 433.17K | -6.0% | $22.25M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 6 | D. E. Shaw & Co. ✦ | 410.68K | +12.3% | $21.10M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 7 | Norges Bank ✦ (passive) | 391.06K | New | $20.09M | 0.0% | New | 1 | SEC ↗ |
| 8 | Millennium Management ✦ | 247.19K | -61.6% | $12.70M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 9 | Wellington Management ✦ | 116.11K | -15.1% | $5.96M | 0.0% | ▼ Trim | 4 | SEC ↗ ×4 |
| 10 | Two Sigma Investments ✦ | 29.28K | -67.9% | $1.50M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 16.22K | 0.0% | $833,428 | 0.0% | Held | 4 | SEC ↗ ×4 |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Adage Capital Partners | $26.20M | 0.0% |
| Norges Bank | $20.09M | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 252 holders, 45.11M shares, $3.08B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 66 sh · $5,281
Director · 11.68K sh · $914,503
Director · 759 sh · $59,961
Officer · 5.39K sh · $484,740
Officer · 1.59K sh · $135,150
Officer · 4.56K sh · $387,940
Officer · 1.59K sh · $143,100
Officer, Director · 7.10K sh · $640,917
Officer, Director · 2.90K sh · $264,683
Officer · 5.39K sh · $457,895
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology